학술논문
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101.
Document Type
Article
Author
Skendros, Panagiotis; Germanidis, Georgios; Mastellos, Dimitrios C.; Antoniadou, Christina; Gavriilidis, Efstratios; Kalopitas, Georgios; Samakidou, Anna; Liontos, Angelos; Chrysanthopoulou, Akrivi; Ntinopoulou, Maria; Kogias, Dionysios; Karanika, Ioanna; Smyrlis, Andreas; Cepaityte, Dainora; Fotiadou, Iliana; Zioga, Nikoleta; Mitroulis, Ioannis; Gatselis, Nikolaos K.; Papagoras, Charalampos; Metallidis, Simeon
Source
Subject
*COMPLEMENT (Immunology)
*COMPLEMENT receptors
*SARS-CoV-2
*COMPLEMENT inhibition
*IMMUNOGLOBULIN M
*CIRCULATING tumor DNA
*POST-acute COVID-19 syndrome
*
*
*
*
*
*
Language
ISSN
2375-2548
Abstract
The article discusses research which focused on the use of compstatin AMY-101 in central complement protein C3 inhibition in severe coronavirus disease 2019 (COVID-19). Topics explored include the involvement of C3-mediated pathways in pathogenic processes that tend to aggravate COVID-19, the clinical outcomes particularly respiratory function observed following AMY-101 administration, and the possible causes of residual C3 activity during treatment with AMY-101.